Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 272 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Spondylarthropathy Clear all

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Arthritis, Psoriatic, Psoriasis
Interventions: fludarabine; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Arthritis, Psoriatic
Interventions: JNJ-88545223, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more

Conditions: Arthritis, Psoriatic
Interventions: Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Mesa, Arizona • Upland, California • Denver, Colorado + 15 more

Conditions: Psoriatic Arthritis
Interventions: 210 mg brodalumab, 140 mg brodalumab, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Peoria, Arizona • Little Rock, Arkansas • Cypress, California + 26 more

Conditions: Ankylosing Spondylitis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Sarasota, Florida • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Spondylitis, Ankylosing
Interventions: CC-99677, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more

Conditions: Inflammatory Bowel Diseases
Interventions: Serial Biopsy; Procedure
Lead sponsor: Terrence A Barrett; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Inflammatory Bowel Diseases (IBD), Ankylosing Spondylitis (AS)
Interventions: Pinch biopsies, Flexible sigmoidoscopy; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Psoriatic Arthritis
Interventions: Guselkumab, Golimumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more

Conditions: Spondylitis, Ankylosing
Interventions: Anti-Tumor Necrosis Factor; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions: Pre-filled Auto-injector Containing Placebo; Device
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 20 Years to 100 Years
Enrollment: 521,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spondyloarthropathies
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 32
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more

Conditions: Arthritis, Psoriatic
Interventions: Tofacitinib, Methotrexate, Placebo Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165 Capsule, BMS-986165 Tablet; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more

Conditions: Arthritis, Psoriatic Arthritis
Interventions: Mobile Application; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Psoriatic Arthritis
Interventions: Direct to patient PsA Screening Questionnaire; Other
Lead sponsor: Jessica Walsh; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Fused Vertebrae, Ankylosing Spondylitis, Sagittal Deformities, Thoracolumbar Kyphosis
Interventions: Experimental: Montage Bone Hemostat; Device
Lead sponsor: Abyrx, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Nonradiographic Axial Spondyloarthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 14
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 11 more

Search by objective public record fields.

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Psoriatic Arthritis D2P Screening

Clinical Investigation of MONTAGE in Adults With Spinal Deformity Undergoing Pedicle Subtraction Osteotomy

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis